Research Article
BibTex RIS Cite

Kanser Tedavisinde Bağışıklık Sistemine Yönelik Yeni Tedavi Yaklaşımları

Year 1990, Volume: 43 Issue: 2, 357 - 370, 30.06.1990

Dilek Dinçol

Abstract

İmmünoterapi, sınırlı bir antitümöral etki gösterebilmektedir. Bugünkü görüşlere göre, immünoterapi ile ancak 109 veya daha az sayıda tümör hücresinin ortadan kaldırılması mümkün olabilmektedir. İmmünoterapide pek çok yaklaşım denenmiştir. Biyolojik yanıt degiştiriciler (Biological Response Modifier) olarak isimlendirilen bu maddelerin çoğu nonspesifik immünstimülan etki yapmaktadır (Tablo 1). Örneğin; Corynebacterium parvum retiküloendotelyal sistem aktivitesini artırmakta, levamisol bazı hastalarda timusa bağlı bağışıklık sistemindeki baskılanmayı ortadan kaldırmakta, BCG ise genel bağışıklık yanıtını güçlendirmektedir. Bu günkü çalışmaların çoğu bağışıklık sistemine ait hücreler (özellikle lenfositler) ile bu hücrelerden salınan çeşitli maddeler (sitokin/lenfokin) üzerinde yoğunlaşmaktadır.

Keywords

immunotherapy immunity tumor cell

References

  • 1. Bergmann L Weidmann E Burgent Betal: Influence of various cytokines on the induction and Iytic activity of Iymphokine activated killer (LAK) celiş, 20d BICON Abstract Book (266), 1989.
  • 2. Fisher RI Coltman CA Doroshow SH et al : Metastatic renal cancer treated with interleukin-2 end Iymphokine activated killer cells : Ann Mmt. Med. 108 : 518-523, 198.
  • 3. Fisher B Fackard B Carrasgrülo J et al : Traffic of tumor infiltrating iymphocytes (TIL) to metastatic tumor deposits; Human studies, Proc Am Soc. Clin Oncol 7 ; 247, 1988 (abstr).
  • 4. Figlin RA : Bictherapy With Interferon - 1988, Semin In Oncol 15(6) : 3-9, 198B
  • 5. Greenbeg PD ; Tumor Immunology In Basic and Clinical Immunologypp. 186- 196, 1987.
  • 6. Hamblin AS : Lymphokines and Interleukins. rms (Supp 0). 39-41, 1988.
  • 7. ligo M Sakurai M Tamura Tet all : In vivo activity of multiple injections of recombinant interlenkin-2, alons and in combination with three different types of recombinant interferon, on various syngeneic murine tümors. Cancer Res 48: 260-264, 1988. n
  • 8. Melntosh JK Mule JJ Merino MJ et al : Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and yezombinan tumor necrosis factor-Cancer Res 48 : 4011-4017, 1988, ii
  • 9. Miller RA Maloney DG Warık Ret al : Treatmentof B cell Iymphoma with me noklonal anti-idiotype antibody. N. Engl J Med 306 : 517-522, 1982.
  • 10. Mitchell MS Kempf RA Harel N et al : Effectiveness and tolerahility of low dose eyclophosphamide and low dose intravenous interleukin-2 in disseminated melanoma, J Clin Oncol 3 : 400-424, 1988.
  • 11. Morgan PA Ruscetti FW Gallo R : Selective in vitro growth of T-iymphocytes from normal human bone marrows, Science 193 : 1007-1008, 1978,
  • 12. Mule JJ Yang JC Lafreniere AL et al : Identification of cellular mechanisms operational in vivo during the repression of established pulmonary metastases by the sistemic administation of hign dose recombinant interleukin-2. J immunol 139 : 285-204, 1987,
  • 13. Oldham RK Smalley RV : Newer Methods of Cancer Treatment. In CANCER Principles and Practive of Oncology (Ed. Devita VT Jr, Hellman S$, Rosenberg SA) pp. 2223-2245, 1985,
  • 14. Parkinson DR : Mmterleukin-2 in Cancer Therapy, Sami in Oncol 15 (6) : 10-85, 1988. LE
  • 15. Rosenberg SA Lotze MT Muul LM etal: A progres report on the treatment ol 157 patients with advanced cancer using Iymphokine-activated killer cells and interleukin 2 or high dose interleukin-2 alone, N Engi J Med 316 : 889-897, 1987.
  • 16. Shiloni E Eisenthal A Sacks Detal : Antibody dependent cellular eytotoxicity mediated by murinhe Iymphocytes activated in recombinant interleukin. J Immunol 138 : 1992-1998, 1987. i
  • 17. Topalian S and Rosenberg S : Tumor Infiltrating İLymphocytes in Cancer Therapy. 2nd BICON Abstracts Book, 268, 1989.
  • 18. Topalian SL Solomon D Aus FPetal: İmmunotherapy of patients with advanced cancer using tumaor-infiltrating Iymphocytes and recombinant interleukin-2. A pilot study. J Clin Öncol 16 : 839-853, 1988.
  • 19. Weber JS Jay G Tamaka K et al : Immunotherapy of a murine tumor with interleukin-2 : Increased sersitivity after MHC Class I gene transfection. J Exp Med 166 : 1716-1733, 1987

New Treatment Approaches For The Immune System In Cancer Treatment

Year 1990, Volume: 43 Issue: 2, 357 - 370, 30.06.1990

Dilek Dinçol

Abstract

References

  • 1. Bergmann L Weidmann E Burgent Betal: Influence of various cytokines on the induction and Iytic activity of Iymphokine activated killer (LAK) celiş, 20d BICON Abstract Book (266), 1989.
  • 2. Fisher RI Coltman CA Doroshow SH et al : Metastatic renal cancer treated with interleukin-2 end Iymphokine activated killer cells : Ann Mmt. Med. 108 : 518-523, 198.
  • 3. Fisher B Fackard B Carrasgrülo J et al : Traffic of tumor infiltrating iymphocytes (TIL) to metastatic tumor deposits; Human studies, Proc Am Soc. Clin Oncol 7 ; 247, 1988 (abstr).
  • 4. Figlin RA : Bictherapy With Interferon - 1988, Semin In Oncol 15(6) : 3-9, 198B
  • 5. Greenbeg PD ; Tumor Immunology In Basic and Clinical Immunologypp. 186- 196, 1987.
  • 6. Hamblin AS : Lymphokines and Interleukins. rms (Supp 0). 39-41, 1988.
  • 7. ligo M Sakurai M Tamura Tet all : In vivo activity of multiple injections of recombinant interlenkin-2, alons and in combination with three different types of recombinant interferon, on various syngeneic murine tümors. Cancer Res 48: 260-264, 1988. n
  • 8. Melntosh JK Mule JJ Merino MJ et al : Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and yezombinan tumor necrosis factor-Cancer Res 48 : 4011-4017, 1988, ii
  • 9. Miller RA Maloney DG Warık Ret al : Treatmentof B cell Iymphoma with me noklonal anti-idiotype antibody. N. Engl J Med 306 : 517-522, 1982.
  • 10. Mitchell MS Kempf RA Harel N et al : Effectiveness and tolerahility of low dose eyclophosphamide and low dose intravenous interleukin-2 in disseminated melanoma, J Clin Oncol 3 : 400-424, 1988.
  • 11. Morgan PA Ruscetti FW Gallo R : Selective in vitro growth of T-iymphocytes from normal human bone marrows, Science 193 : 1007-1008, 1978,
  • 12. Mule JJ Yang JC Lafreniere AL et al : Identification of cellular mechanisms operational in vivo during the repression of established pulmonary metastases by the sistemic administation of hign dose recombinant interleukin-2. J immunol 139 : 285-204, 1987,
  • 13. Oldham RK Smalley RV : Newer Methods of Cancer Treatment. In CANCER Principles and Practive of Oncology (Ed. Devita VT Jr, Hellman S$, Rosenberg SA) pp. 2223-2245, 1985,
  • 14. Parkinson DR : Mmterleukin-2 in Cancer Therapy, Sami in Oncol 15 (6) : 10-85, 1988. LE
  • 15. Rosenberg SA Lotze MT Muul LM etal: A progres report on the treatment ol 157 patients with advanced cancer using Iymphokine-activated killer cells and interleukin 2 or high dose interleukin-2 alone, N Engi J Med 316 : 889-897, 1987.
  • 16. Shiloni E Eisenthal A Sacks Detal : Antibody dependent cellular eytotoxicity mediated by murinhe Iymphocytes activated in recombinant interleukin. J Immunol 138 : 1992-1998, 1987. i
  • 17. Topalian S and Rosenberg S : Tumor Infiltrating İLymphocytes in Cancer Therapy. 2nd BICON Abstracts Book, 268, 1989.
  • 18. Topalian SL Solomon D Aus FPetal: İmmunotherapy of patients with advanced cancer using tumaor-infiltrating Iymphocytes and recombinant interleukin-2. A pilot study. J Clin Öncol 16 : 839-853, 1988.
  • 19. Weber JS Jay G Tamaka K et al : Immunotherapy of a murine tumor with interleukin-2 : Increased sersitivity after MHC Class I gene transfection. J Exp Med 166 : 1716-1733, 1987
There are 19 citations in total.

Details

Primary Language Turkish
Subjects Clinical Oncology
Journal Section Articles
Authors

Dilek Dinçol This is me

Publication Date June 30, 1990
Published in Issue Year 1990 Volume: 43 Issue: 2

Cite

APA Dinçol, D. (1990). Kanser Tedavisinde Bağışıklık Sistemine Yönelik Yeni Tedavi Yaklaşımları. Ankara Üniversitesi Tıp Fakültesi Mecmuası, 43(2), 357-370.
AMA Dinçol D. Kanser Tedavisinde Bağışıklık Sistemine Yönelik Yeni Tedavi Yaklaşımları. Ankara Üniversitesi Tıp Fakültesi Mecmuası. June 1990;43(2):357-370.
Chicago Dinçol, Dilek. “Kanser Tedavisinde Bağışıklık Sistemine Yönelik Yeni Tedavi Yaklaşımları”. Ankara Üniversitesi Tıp Fakültesi Mecmuası 43, no. 2 (June 1990): 357-70.
EndNote Dinçol D (June 1, 1990) Kanser Tedavisinde Bağışıklık Sistemine Yönelik Yeni Tedavi Yaklaşımları. Ankara Üniversitesi Tıp Fakültesi Mecmuası 43 2 357–370.
IEEE D. Dinçol, “Kanser Tedavisinde Bağışıklık Sistemine Yönelik Yeni Tedavi Yaklaşımları”, Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol. 43, no. 2, pp. 357–370, 1990.
ISNAD Dinçol, Dilek. “Kanser Tedavisinde Bağışıklık Sistemine Yönelik Yeni Tedavi Yaklaşımları”. Ankara Üniversitesi Tıp Fakültesi Mecmuası 43/2 (June1990), 357-370.
JAMA Dinçol D. Kanser Tedavisinde Bağışıklık Sistemine Yönelik Yeni Tedavi Yaklaşımları. Ankara Üniversitesi Tıp Fakültesi Mecmuası. 1990;43:357–370.
MLA Dinçol, Dilek. “Kanser Tedavisinde Bağışıklık Sistemine Yönelik Yeni Tedavi Yaklaşımları”. Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol. 43, no. 2, 1990, pp. 357-70.
Vancouver Dinçol D. Kanser Tedavisinde Bağışıklık Sistemine Yönelik Yeni Tedavi Yaklaşımları. Ankara Üniversitesi Tıp Fakültesi Mecmuası. 1990;43(2):357-70.
 Download Cover Image